Abstract
DCVax(®) (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering dendritic cell based therapeutic vaccines for a variety of cancers, including glioblastoma multiforme (GBM). DCVax(®)-L, one of the implementations of the DCVax platform, provides personalized active immunotherapy composed of autologous dendritic cells pulsed with autologous whole tumor lysate. Clinical trials with DCVax-L for GBM included previous Phase I/II clinical trials and an ongoing Phase III trial. Preliminary reports of patient outcomes after administration of the DCVax-L vaccine provide a promising therapeutic paradigm for patients with both initially diagnosed and recurrent GBM. Here we evaluate the current literature and clinical experience with the DCVax platform, with a particular focus on GBM treatment.
References
Jul 1, 1981·Journal of Neurosurgery·D D BignerC J Wikstrand
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·R H BoboE H Oldfield
Jan 10, 2002·Journal of Neurosurgery·M LacroixR Sawaya
Jun 3, 2004·Nature Reviews. Drug Discovery·Maciej S Lesniak, Henry Brem
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 17, 2006·Acta neurochirurgica·M WestphalUNKNOWN Executive Committee of the Gliadel Study Group
Feb 16, 2007·European Journal of Immunology·Cindy Aerts-ToegaertKarine Breckpot
Aug 4, 2007·The Oncologist·Jeffrey Weber
Nov 15, 2008·The Oncologist·Jeffrey Weber
Apr 2, 2009·Expert Opinion on Investigational Drugs·Christopher J Wheeler, Keith L Black
Nov 18, 2009·Expert Opinion on Biological Therapy·Mayer Fishman
Mar 23, 2011·Journal of Neurosurgery·Nader SanaiMitchel S Berger
Apr 28, 2011·Expert Opinion on Biological Therapy·Alia Hdeib, Andrew E Sloan
May 6, 2011·Immunotherapy·Tony AvrilVéronique Quillien
Jun 23, 2011·Expert Review of Vaccines·Christopher J Wheeler, Keith L Black
Jul 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Joost LesterhuisCarl G Figdor
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivek SubbiahRazelle Kurzrock
Feb 22, 2012·Current Drug Discovery Technologies·Divya AjayJohn H Sampson
Feb 22, 2012·Current Drug Discovery Technologies·Ankit I MehtaJohn H Sampson
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jul 7, 2012·Future Oncology·Alia Hdeib, Andrew Sloan
Mar 14, 2013·Oncoimmunology·Lana E KandalaftGeorge Coukos
Aug 2, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S WilgenhofB Neyns
Oct 30, 2013·Neuro-oncology·Quinn T OstromJill S Barnholtz-Sloan
Apr 16, 2014·Journal of Nanoscience and Nanotechnology·Minghui LiQun Wang
Citations
Nov 13, 2015·Future Oncology·Evidio Domingo-Musibay, Evanthia Galanis
Sep 10, 2015·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Verena SchummerThomas Hinz
Jul 14, 2016·Expert Opinion on Biological Therapy·Neha KamranMaria G Castro
Aug 9, 2016·Expert Review of Vaccines·Teilo H Schaller, John H Sampson
Dec 21, 2016·Immunotherapy·Evan K WinogradRobert A Fenstermaker
Mar 14, 2017·Expert Opinion on Biological Therapy·Mayuri ChandranMaria G Castro
Oct 11, 2017·CNS Oncology·Vincent HealyJohn Caird
Aug 29, 2018·International Journal of Molecular Sciences·Virgil E J C SchijnsApostolos Stathopoulos
Jul 6, 2019·PloS One·Thomas W MillerJames Inglese
Apr 3, 2020·PloS One·Teresa L BurgessThomas W Miller
Apr 9, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Visish M SrinivasanAmy B Heimberger
Jul 18, 2018·Blood Advances·Derek Hoi-Hang Ho, Roger Hoi-Fung Wong
Dec 22, 2016·CNS Oncology·Harjus S BirkNicholas A Butowski
Nov 1, 2017·Human Vaccines & Immunotherapeutics·Ziren KongWenbin Ma
Apr 2, 2021·Frontiers in Molecular Neuroscience·Kaushik BanerjeeMaria G Castro
Sep 3, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TouatK L Ligon